Stay updated on Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.

Latest updates to the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page revision updates from v3.4.1 to v3.4.2 and does not affect study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision label on the page changed from v3.4.0 to v3.4.1. No visible changes to study content or functionality were observed.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing the previous revision v3.3.3.SummaryDifference0.0%

- Check62 days agoChange DetectedThe study's Locations section was updated: numerous new sites were added across the United States and internationally (including Belgium, France, Germany, Korea, Spain, and the United Kingdom) and several existing sites were removed, expanding and reorganizing where the trial is conducted.SummaryDifference3%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no visible changes to the study details content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check99 days agoChange DetectedThe government funding and NIH operating status notice was removed from the page; core trial details such as study plan, locations, and eligibility remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.